Completed

ZPACTNon-small Cell Lung Cancer Study US75 (Z-PACT)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

zoledronic acid

+ Taxotere

+ Carboplatin

Drug
Who is being recruted

Bronchial Neoplasms+16

+ Bronchial Neoplasms

+ Bronchial Neoplasms

Over 18 Years
See all eligibility criteria
How is the trial designed

Prevention Study

Phase 3
Interventional
Study Start: April 2004
See protocol details

Summary

Principal SponsorNovartis Pharmaceuticals
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2004

Actual date on which the first participant was enrolled.

This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.

Official TitleNon-small Cell Lung Cancer Study US75 (Z-PACT) 
NCT00093717NCT00086268
Principal SponsorNovartis Pharmaceuticals
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

250 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bronchial NeoplasmsBronchial NeoplasmsBronchial NeoplasmsCarcinoma, BronchogenicCarcinoma, BronchogenicCarcinoma, BronchogenicCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell LungLung DiseasesLung NeoplasmsLung NeoplasmsLung NeoplasmsNeoplasmsNeoplasms by SiteRespiratory Tract DiseasesRespiratory Tract NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms

Criteria

Inclusion Criteria: * Male or Female patients at least of 18 years old * Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery * Women must not be pregnant or attempting to become pregnant * Able and willing to sign informed consent Exclusion Criteria: * Patients with cancer that has spread to the bone * Patients with cancer that has spread to the brain who are receiving treatment * Patients with kidney disease * Patients treated with other investigational drugs

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
4mg monthly for 12 months from date of first chemotherapy dose

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 80 locations

Suspended

Clinical Research Consultants

Hoover, United StatesSee the location
Suspended

Arizona Oncology Assoc.

Tucson, United States
Suspended

NEA Clinic

Jonesboro, United States
Suspended

Highlands Oncology Group

Springdale, United States
Completed80 Study Centers